Integral Diagnostics Ltd. (IDX) AI Stock Analysis

• Market Cap: AU$1.07B
• Dividend Yield: 2.28%
• Average Volume (3M): 1.48M
• Price to Earnings (P/E): 188.8
• Beta (1Y): 0.15
• Revenue Growth: 33.54%
• EPS Growth: N/A
• Country: AU
• Employees: 1,977
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.07
• Shares Outstanding: 372,626,800
• 10 Day Avg. Volume: 762,421
• 30 Day Avg. Volume: 1,476,766
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$3.43
• Price Target Upside: 20.35% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 61 Neutral
• Price Target: AU$3.00 ▲(5.26% Upside)

Integral Diagnostics Ltd. exhibits strong technical momentum, which is the most significant positive factor. However, the high P/E ratio suggests overvaluation, posing a risk to potential investors. Financial performance shows growth but is hindered by low profitability and cash flow concerns. The absence of earnings call data and notable corporate events limits additional insights.

Integral Diagnostics Ltd. Business Overview & Revenue Model

Company Description

Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand. It provides services through 67 radiology clinics. The company was incorporated in 2008 and is headquartered in Melbourne, Australia.

How the Company Makes Money

Integral Diagnostics Ltd. makes money primarily by offering a comprehensive range of diagnostic imaging services. Revenue is generated through the fees charged for imaging services, which are typically paid by patients, private health insurance, or government healthcare programs. The company's key revenue streams include direct payments from patients and reimbursements from health insurance providers and government agencies. Significant partnerships with hospitals and healthcare providers enhance its service offerings and accessibility, contributing to its earnings. Additionally, IDX may leverage technology and innovation to streamline operations and improve service delivery, further bolstering its financial performance.

Integral Diagnostics Ltd. Financial Statement Overview

Summary

Integral Diagnostics Ltd. shows strong revenue growth and operational efficiency, as evidenced by high gross profit margins. However, the company faces challenges in converting this growth into net income, reflected in low net profit margins and return on equity. The balance sheet shows improved leverage, but cash flow concerns persist due to declining free cash flow. Overall, while the company is on a growth trajectory, it needs to focus on enhancing profitability and cash flow management to ensure sustainable financial health.

Income Statement

Integral Diagnostics Ltd. has demonstrated strong revenue growth with a 27.66% increase in the latest year, indicating a robust expansion trajectory. The gross profit margin remains high at 95.52%, showcasing operational efficiency. However, the net profit margin is low at 0.75%, suggesting challenges in translating revenue growth into net income. The EBIT and EBITDA margins are moderate, reflecting stable operational performance but room for improvement in cost management.

Balance Sheet

The company's debt-to-equity ratio has improved to 0.84, indicating a better balance between debt and equity compared to previous years. However, the return on equity is low at 0.67%, pointing to limited profitability for shareholders. The equity ratio is stable, suggesting a solid asset base, but the company needs to enhance its profitability metrics to strengthen its financial position further.

Cash Flow

Operating cash flow remains positive, but the free cash flow has declined significantly by 58.96%, raising concerns about cash generation capabilities. The operating cash flow to net income ratio is moderate, indicating some efficiency in converting income into cash. However, the free cash flow to net income ratio is low, suggesting potential liquidity challenges if the trend continues.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	627.22M	627.22M	469.70M	440.10M	358.74M	348.81M
Gross Profit	163.28M	599.09M	446.78M	97.76M	83.84M	92.19M
EBITDA	96.64M	87.70M	12.33M	92.74M	69.90M	88.94M
Net Income	4.67M	4.67M	-60.70M	25.04M	14.60M	31.27M
Balance Sheet
Total Assets	1.43B	1.43B	744.28M	839.01M	783.01M	654.90M
Cash, Cash Equivalents and Short-Term Investments	52.10M	52.10M	42.44M	33.85M	123.19M	62.20M
Total Debt	585.01M	585.01M	357.80M	365.08M	340.99M	308.36M
Total Liabilities	732.53M	732.53M	442.57M	465.96M	435.77M	400.16M
Stockholders Equity	693.00M	693.00M	301.71M	373.05M	347.24M	254.74M
Cash Flow
Free Cash Flow	14.01M	14.01M	42.28M	27.42M	9.33M	49.30M
Operating Cash Flow	73.77M	73.77M	66.16M	71.42M	37.10M	69.57M
Investing Cash Flow	-64.99M	-64.99M	-27.90M	-128.96M	-55.69M	-56.66M
Financing Cash Flow	710.00K	710.00K	-29.45M	-31.85M	81.13M	-7.83M

Integral Diagnostics Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.85
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IDX, the sentiment is Neutral. The current price of 2.85 is below the 20-day moving average (MA) of 2.88, above the 50-day MA of 2.77, and above the 200-day MA of 2.59, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 51.83 is Neutral, neither overbought nor oversold. The STOCH value of 34.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:IDX.

Integral Diagnostics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SHL	73 Outperform	10.74B	20.33	―	4.97%	9.44%	-0.37%
ACL	70 Outperform	489.48M	14.58	―	4.98%	6.73%	37.16%
IDX	61 Neutral	AU$1.07B	188.82	0.94%	2.28%	33.54%	―
MVF	55 Neutral	261.06M	10.44	―	7.79%	6.65%	―
HLS	46 Neutral	548.23M	-1.06	―	―	-23.02%	33.11%
GSS	41 Neutral	62.46M	-2.93	-40.13%	―	62.81%	16.37%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Integral Diagnostics Ltd. Corporate Events

Integral Diagnostics to Host FY25 Results Conference Call

Integral Diagnostics Limited announced it will hold a group investor conference call on August 26, 2025, following the release of its FY25 results. This event is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and operations.

The most recent analyst rating on (AU:IDX) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.

Integral Diagnostics Faces Legal Claim Over Earn-Out Dispute

Integral Diagnostics Ltd. has been served with a legal claim by the Vendors of the Imaging Queensland business, which it acquired in 2019. The Vendors are seeking damages related to an earn-out valuation dispute, which was previously determined by an independent expert to be $2.2 million. Despite efforts by Integral to resolve the issue based on this valuation, the Vendors have initiated legal proceedings. Integral plans to defend itself in this litigation, which could have implications for its financial provisioning and stakeholder relations.

The most recent analyst rating on (AU:IDX) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.

Integral Diagnostics CEO Announces Retirement, Initiates Leadership Transition

Integral Diagnostics (IDX) announced the upcoming retirement of its Managing Director and CEO, Dr. Ian Kadish, effective at the end of FY26. Dr. Kadish has significantly contributed to the company’s growth, transforming it into the second largest radiology provider in Australia and a notable presence in New Zealand. The company is conducting an international search for his successor, aiming for a seamless transition to maintain service standards and capitalize on recent synergies from its merger with Capitol Health.

The most recent analyst rating on (AU:IDX) stock is a Buy with a A$3.50 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.

Integral Diagnostics to Present at 2025 Macquarie Australia Conference

Integral Diagnostics announced its participation in the 2025 Macquarie Australia Conference, where it will present its latest developments. This engagement underscores IDX’s commitment to maintaining its leadership position in the medical imaging industry and highlights its ongoing efforts to enhance service quality and patient care.

Challenger Limited Ceases to be Substantial Holder in Integral Diagnostics

Challenger Limited has announced that it and its associated entities have ceased to be substantial holders in Integral Diagnostics Limited. This change in holdings may impact Integral Diagnostics’ shareholder composition and influence its market position, as substantial holders often have significant voting power and influence over company decisions.